Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
1(17%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
1
17%
Ph not_applicable
1
17%
Ph phase_1
4
67%

Phase Distribution

4

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
4(66.7%)
Phase 2Efficacy & side effects
1(16.7%)
N/ANon-phased studies
1(16.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

6

all time

Status Distribution
Active(1)
Completed(4)
Other(1)

Detailed Status

Completed4
unknown1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
1
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 14 (66.7%)
Phase 21 (16.7%)
N/A1 (16.7%)

Trials by Status

unknown117%
active_not_recruiting117%
completed467%

Recent Activity

1 active trials
Showing 5 of 6
active_not_recruitingphase_1

huCART-meso + VCN-01 in Pancreatic and Ovarian Cancer

NCT05057715
completedphase_2

Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic Cancer

NCT05673811
completednot_applicable

Evaluate Safety and the Oncolitic Adenovirus VCN-01 Activity in Patients With Refractory Retinoblastoma

NCT03284268
unknownphase_1

Safety,Tolerability,and Efficacy of VCN-01 With Durvalumab in R/M Head and Neck Squamous Cell Carcinoma

NCT03799744
completedphase_1

Phase I Dose Escalation Study of Intravenous VCN-01 With or Without Gemcitabine and Abraxane® in Patients With Advanced Solid Tumors

NCT02045602
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT05057715Phase 1

huCART-meso + VCN-01 in Pancreatic and Ovarian Cancer

Active Not Recruiting
NCT05673811Phase 2

Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic Cancer

Completed
NCT03284268Not Applicable

Evaluate Safety and the Oncolitic Adenovirus VCN-01 Activity in Patients With Refractory Retinoblastoma

Completed
NCT03799744Phase 1

Safety,Tolerability,and Efficacy of VCN-01 With Durvalumab in R/M Head and Neck Squamous Cell Carcinoma

Unknown
NCT02045602Phase 1

Phase I Dose Escalation Study of Intravenous VCN-01 With or Without Gemcitabine and Abraxane® in Patients With Advanced Solid Tumors

Completed
NCT02045589Phase 1

A Phase I Dose Escalation Study of Intratumoral VCN-01 Injections With Gemcitabine and Abraxane® in Patients With Advanced Pancreatic Cancer

Completed

All 6 trials loaded

Drug Details

Intervention Type
GENETIC
Total Trials
6